10xBio Provides Update on Patent Portfolio
July 15, 2023
SAN DIEGO (July 15, 2023) – 10xBio, LLC, a privately-held biotechnology company, announces that in the past 24 months it has been issued 3 patents from the U.S. Patent and Trademark Office. These patents broadly cover formulations and methods of the company’s drug product being developed for minimally invasive body contouring and include US 9,844,520, US 10,485,767, and US 11,065,210. These patents add to the company’s substantial portfolio including one additional U.S. patent (9,351,945) and 11 international patents covering Europe, Canada, Australia, and select Asian countries. Exclusivity is provided into 2035.
John Dobak, M.D., the company’s Managing Director and Chairman commented, “These patents provide substantial protection for our core body contouring product, 10XB101, in Phase 2 clinical development.”
About 10xBio
We are biotechnology company that focuses on new uses for existing therapies and technologies. This strategy allows us to build on existing safety profiles and leverage known mechanisms of action, resulting in a streamlined development and regulatory process. Our most advanced asset, 10XB101, is a pharmaceutical product that addresses unmet needs in dermatologic medicine. For more information, visit us at www.10xBio.com.
Contact
10xBio, LLC.
John Dobak, M.D.
Managing Director and Chairman
info@10xbio.com